Tags Archive Navigation
icon
-
Media ReleaseNovartis expands Zolgensma manufacturing capacity with approval of multi-product North Carolina facility
-
Media ReleaseNovartis data again demonstrate age-appropriate development when Zolgensma is used presymptomatically, and post-hoc data reveal SMA Type 1 patients could speak, swallow and maintain airway protection
-
Media ReleaseNovartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021
-
Media ReleaseNovartis: a enregistré, en 2021, une croissance du chiffre d’affaires net à un chiffre dans le milieu de la fourchette, une expansion de la marge et une avancée du robuste pipeline
-
Media ReleaseNovartis erzielt 2021 ein Umsatzwachstum im mittleren einstelligen Bereich, verbessert die Margen und treibt die solide Pipeline voran
-
Media ReleaseNovartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19
-
Media ReleaseNovartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis
-
Media ReleaseNovartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms
-
StoryWhen it comes to cancer, there’s power in a good partner
-
StorySolving the puzzle of immunotherapy
-
StoryTo make a difference, start with patients
-
Media ReleaseNovartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
Pagination
- ‹ Previous page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- …
- 16
- › Next page